Index Day reports (ADR)...59, 125
|
|
- Lewis Summers
- 5 years ago
- Views:
Transcription
1 Index 15-Day reports (ADR)...59, Day reports (ADR) Day reports (ADR)...59 ADR reporting system Reporting by pharmaceutical companies ADR Reporting System Reporting by MHLW Advanced Review with Electronic Data Promotion Group...8 Adverse Drug Reaction (ADR) and Infection Reporting...29 Age classification for pediatric use AIDS Research Center (NIID)...10 Approval and Licensed Data Required for Approval Applications...68 Approval and licenses Acceptance of foreign clinical trial data...72 Application forms...32 Data to be Attached to Approval Application...71 Approval and Licenses Approval Applications for Drugs Manufactured Overseas...42 Transfer of Marketing Approvals...42 Approval review...63 Approval System for Regenerative Medicine...40 Article 42 of the Pharmaceutical Affairs Law...45 Biological products...18 Biosimilar Products...41, 87 Biotechnological products...85 Blood and Blood Products Division (PFSB)...4 Brand names of prescriptions drugs bridging studies...72 Certificates Issued by MHLW...43 Classification of reexamination approval Clinical development/studies Phases of studies...79 Clinical Studies...78 Clinical study reports (FSR)...82 Codevelopment of Drugs...42 Combination Products...41 Commentaries on Precautions in package inserts Compliance and Narcotics Division (PFSB)...3 Compliance Reviews...64 Conditional Accelerated Approval System for Pharmaceuticals...40 Common Technical Document (CTD) CTD Module CTD Module 2: Data summaries...70 CTD Module 3: Quality...70 CTD Module 4: Nonclinical study reports...71 CTD Module 5: Clinical study reports...71 Development of New Drugs...56 Dissemination of drug information General Safety information Dissemination of information...29 Dissemination of information on adverse reactions to drugs Drug Master File (DMF)...23 Drug Abuse Control...31 Drug Development Process from Development to Approval...56 Drug Marketing Approvals...32 Drug pricing Drug Safety Update Drug Seller Licensing...23 Drugs Classification...17 Definition...17 Quality Standards Based on Notifications...46 Drugs for Pediatric Use...36 Drugs using materials of human or animal origin...86 Early post-marketing phase vigilance
2 Economic Affairs Division (HPB)...4 Electronic information dissemination Safety information Emergency safety information (Yellow letter) Entries for biological products Entry of generic drugs in the NHI price list GCP General requirements...83 General Affairs Division (PFSB)...2 GMP Compliance review...66 Global harmonization...67 GMP compliance inspection...66 Good Clinical Practice (GCP)...26 Good Laboratory Practice (GLP)...25 Good Laboratory Practice (GLP)...75 Good Manufacturing Practice (GMP)...22 Good Post-marketing Study Practice (GPMSP)...28 Good Vigilance Practice (GVP) Government Batch Test Quality of Drugs...46 GPMSP...28 GPSP Paper Compliance Review and On-site GPSP Surveys for Reexamination and Reevaluation GPSP Guidance-mandatory drugs...17 Guidelines Clinical evaluation...83 Nonclinical Studies...73 Guidelines Concerning Drug Approval Applications...72 Guidelines for bioequivalence Studies...77 Guidelines for General Pharmacological Studies...77 Guidelines for Pharmacokinetic Studies...77 Guidelines for Promoting Optimal Use...40 Guidelines for Stability Tests...74 Guidelines for Toxicity Tests...75 Guidelines on Physicochemical Properties, Specifications, and Tests Methods...73 GVP Health and Medical Services Law for the Aged Health insurance programs Health Policy Bureau (HPB)...4 History of health insurance programs Hokuriku Branch...9 ICH...88 Infectious Diseases Information Center (NIID)...10 Information for drugs which completed reexamination or reevaluation International Conference on Harmonization (ICH)...89 Interview advice meetings...60 Investigational product GMP...84 Investigational products Quality...79 Issues related to the use of determination of unapproved drugs and off-label use Japan Agency for Medical Research and Development (AMED)...9 Japanese Pharmacopoeia (JP)...43 Japanese Pharmacopoeia and Other Standards...43 Kansai Branch...8 Labeling and Package Inserts...24 Labeling of excipients Law Concerning Access to Information...30 Manufacturing Business and Accreditation License...20 Manufacturing/Marketing Approval Application with Electronic Data...34 Manufacturing/Marketing Approvals Manufacturing/Marketing License...19 Marketing Approval Review...32 Marketing Approvals...32 Medical benefits under NHI programs Medical Device Evaluation Division (PFSB)...2 Microdose studies...81 Ministry of Health, Labour and Welfare (MHLW) Organization and function...1 National Institute of Biomedical Innovation...9 National Institute of Health Sciences (Health Sciences)
3 National Institute of Infectious Diseases (NIID)...10 NHI price list NHI reimbursement of medical fees Nonclinical studies Requirements...78 Non-prescription drugs...18 Non-prescription Drugs...71 Office of Cellular and Tissue-based Products (PMDA)...7 Office of Chemical Safety (PFSB)...3 Office of Compliance and Standards (PMDA)...8 Office of Drug Induced Damages (PFSB)...2 Office of Generic Drugs (PMDA)...7 Office of in Vitro Diagnostics (PMDA)...7 Office of International Cooperation...8 Office of International Programs...8 Office of Manufacturing/Quality and Compliance (PMDA)...8 Office of Medical Devices I (PMDA)...7 Office of Medical Devices II (PMDA)...7 Office of Medical Devices III (PMDA)...7 Office of Medical Informatics and Epidemiology(PMDA)...8 Office of New Drug I (PMDA)...6 Office of New Drug II (PMDA)...6 Office of New Drug III (PMDA)...6 Office of New Drug IV (PMDA)...7 Office of New Drug V (PMDA)...7 Office of OTC/Quasi-drugs (PMDA)...7 Office of Review Administration (PMDA)...6 Office of Review Management (PMDA)...6 Office of Safety I (PMDA)...8 Office of Safety II (PMDA)...8 Office of Standards and Guidelines Development (PMDA)...6 Office of Vaccines and Blood Products (PMDA)...7 On-site reviews...65 Orphan Drugs...36 Outline of Pharmaceutical Regulations...17 Outline of prescription of drug information Package inserts Background Guidelines Headings and their sequence Information to supplement package inserts Non-prescription drugs Style and format Package Inserts in English Package inserts of guidance-mandatory drugs Packaging Strategy for World-first Products...38 Paper reviews...65 Patent System...30 Patient-requested Therapy System...27 Periodic infection reports for biological products Periodic safety reports Pharmaceutical Affairs and Food Sanitation Council (PAFSC)...9 Pharmaceutical and Medical Device Act...15 Pharmaceutical Evaluation Division (PFSB)...2 Pharmaceutical Interview Forms (IF) Pharmaceutical Laws...15 Pharmaceutical laws and regulations...15 Pharmaceutical Safety and Environmental Health Bureau (PSEHB)...2 Pharmaceutical Safety Division (PFSB)...3 Pharmaceutical Supervision...47 Pharmaceuticals and Medical Devices Agency, an Independent Administrative Organization...5 Pharmacological studies Requirements...79 Phase I of clinical studies...80 Phase II of clinical studies...80 Phase III of clinical studies...80 Phase IV of clinical studies...81 PMS Post-marketing surveillance (PMS) Precautions (package inserts) Prescription drugs...17 Prescription Drugs...71 Prevention of Medical Accidents...47 Pricing formula for reimbursement price revisions Priority Review System...35 Priority reviews...15 Procedures for Clinical Trials...57 Product Recalls...47 Proper Advertisement...25 Public disclosure of information on new drug development...88 Recent revisions of NHI price list Reevaluation...28 Reevaluation System Reexamination...28 Data and procedures Designated classifications
4 Designation of drugs System Regulations for Imported Drug Management and Quality Control...67 Regulatory Science Strategy Consultations for Regenerative Medicine Products...39 Reimbursement prices for new drugs Research and Development Division (HPB)...4 Restrictive Approval System...36 Risk Management Plan...29 Risk management plan (RMP) Safety flash report ( Safety information Reporting System by Medical Personnel Safety Measures against Bovine Spongiform Encephalitis (BSE)...48 Safety monitoring During clinical studies...59 Safety studies Requirements...79 SOP for PMS Special populations...81 Specified biological products...18 Standards for Biological Materials...45 Structure and Layout of Package Insert for Prescription Drugs Studies of drug interactions...81 Studies of drug metabolites...81 Trial Conducted from a Compassionate Viewpoint (expanded trial)...27 Unapproved Drugs and Drugs of Off-label Use...37 WHO safety monitoring program Yellow letter
5 Participating Company List Under the supervision of Ministry of Health Labour and Welfare Japan, this publication has been updated regularly with the cooperation of the enthusiastic editors below. Leader: Katsunori KURUSU (Chapter 1) (Chapter 2) (Chapter 3) (Chapter 4) (Chapter 5) Sanofi KK Eisai Co, Ltd EA Pharma Co, Ltd Takeda Pharmaceutical Company Limited Daiichi Sankyo Co, Ltd Janssen Pharmaceutical KK MSD KK UCB Japan Co, Ltd Mitsubishi Tanabe Pharma Corporation Shionogi & Co, Ltd Kyowa Hakko Kirin Co, Ltd Chugai Pharmaceutical Co, Ltd Diabetes & Cardiovascular Regulatory Affairs Oncology & Immunology 2 Regulatory Affairs: Katsunori KURUSU Japan Regulatory Affairs: Michiyuki SUZUKI Regulatory Affairs: Tsuyoshi KOBAYASHI Regulatory Affairs: Katsunori INUI New Drug Regulatory Affairs: Yoshiyuki HATTORI Regulatory Development Department: Taihei SHIRASAKA Regulatory Policy & Intelligence: Kanji HIRAI, Jun ONO Regulatory Affairs: Yasuhiro HASEGAWA Regulatory Affairs: Mamoru IKEDA Regulatory Affairs: Kazuyo MARUCHI PV Operations Department: Hiroyuki OHTSUKA Regulatory Intelligence & Management Department: Yuichi TAKIDO, Yasuhiro KITSUTA (Chapter 6) Otsuka Pharmaceutical Co, Ltd Regulatory Affairs Department: Toshio SATO Contact: JAPAN PHARMACEUTICAL MANUFACTURERS ASSOCIATION Office of International Affairs Administrative Office Nihonbashi-Honcho, Chuo-ku, Tokyo , Japan address: jpma.or.jp Phone 81-3 (3241) 0326 Fax 81-3 (3242)
INFORMATION ON JAPANESE REGULATORY AFFAIRS
2017 INFORMATION ON JAPANESE REGULATORY AFFAIRS Regulatory Information Task Force Japan Pharmaceutical Manufacturers Association Pharmaceutical Administration and Regulations in Japan Japan Pharmaceutical
More informationINFORMATION ON JAPANESE REGULATORY AFFAIRS
2018 INFORMATION ON JAPANESE REGULATORY AFFAIRS Regulatory Information Task Force Japan Pharmaceutical Manufacturers Association Pharmaceutical Administration and Regulations in Japan Japan Pharmaceutical
More informationCHAPTER 2 PHARMACEUTICAL LAWS AND REGULATIONS 1. PHARMACEUTICAL LAWS 2. PHARMACEUTICAL AND MEDICAL DEVICE ACT
CHAPTER 2 PHARMACEUTICAL LAWS AND REGULATIONS 1. PHARMACEUTICAL LAWS Pharmaceutical administration in Japan is based on various laws and regulations, consisting mainly of: (1) Pharmaceutical and Medical
More informationINFORMATION IN ENGLISH ON JAPAN REGULATORY AFFAIRS. English Regulatory Information Task Force, Japan. Pharmaceutical Manufacturers Association
2006.3 INFORMATION IN ENGLISH ON JAPAN REGULATORY AFFAIRS English Regulatory Information Task Force, Japan Pharmaceutical Manufacturers Association Pharmaceutical Administration and Regulations in Japan
More informationCHAPTER 2 PHARMACEUTICAL LAWS AND REGULATIONS 1. PHARMACEUTICAL LAWS 2. PHARMACEUTICAL AND MEDICAL DEVICE ACT
CHAPTER 2 PHARMACEUTICAL LAWS AND REGULATIONS 1. PHARMACEUTICAL LAWS Pharmaceutical administration in Japan is based on various laws and regulations, consisting mainly of: (1) Pharmaceutical and Medical
More informationCHAPTER 5 Supply and Dissemination of Drug Safety Management Information
CHAPTER 5 Supply and Dissemination of Drug Safety Management Information Manufacturing/marketing authorization holders of drugs must collect and examine information on proper use of drugs such as information
More informationCHAPTER 5 SUPPLY AND DISSEMINATION OF DRUG SAFETY MANAGEMENT INFORMATION 1. PACKAGE INSERTS
CHAPTER 5 SUPPLY AND DISSEMINATION OF DRUG SAFETY MANAGEMENT INFORMATION Manufacturing/marketing authorization holders of drugs must collect and examine information on proper use of drugs such as information
More informationPharmaceutical Regulations in Japan
Pharmaceutical Regulations in Japan -Generic Drug Review System, MF System- Pharmaceuticals and Medical Devices Agency (PMDA) Miho Tabata Office of Generic Drugs Pharmaceuticals and Medical Devices Agency
More informationCHAPTER 3 DRUG DEVELOPMENT. 1.1 Development of New Drugs 1. PROCESS FROM DEVELOPMENT TO APPROVAL
CHAPTER 3 DRUG DEVELOPMENT indications, which are clearly different from those of drugs, which have already been approved for manufacture and marketing. 1.1 Development of New Drugs 1. PROCESS FROM DEVELOPMENT
More informationCHAPTER 3 Drug Development
CHAPTER 3 Drug Development 1. PROCESS FROM DEVELOPMENT TO APPROVAL New drugs are defined as drugs with active ingredients, dosage, administration route, or indications, which are clearly different from
More informationContents. 1. Administrative Organizations and Affairs under Jurisdiction for Veterinary Medical Devices
Assurance System of Quality, Performance, and Safety of Veterinary Medical Devices Based on the Law for Ensuring the Quality, Efficacy, and Safety of Drugs and Medical Devices Animal Products Safety Division
More informationOutline of Regulation System of Veterinary Medicinal Products (VMPs) in Japan
Outline of Regulation System of Veterinary Medicinal Products (VMPs) in Japan -To ensure quality, efficacy and safety of VMPs based on the Pharmaceutical Affairs Law - Animal Products Safety Division,
More informationPharmaceuticals and Medical Devices Agency, Japan. Profile of Services
Pharmaceuticals and Medical Devices Agency, Japan Profile of Services 2017-2018 Our Philosophy PMDA continues to improve the public health and safety of our nation by reviewing applications for marketing
More informationPharmacovigilance - Regulatory perspective -
Pharmacovigilance - Regulatory perspective - Junko Sato Director for Risk Management, Office of Safety Pharmaceuticals and Medical Devices Agency (PMDA) Agenda Concept of Phamacovigilance Current Regulation
More informationKFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar
KFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar Kyung-Min Baek, Ph.D. Recombinant Protein Products Division Korea Food and Drug Administration(KFDA) Biopharmaceuticals A biopharmaceutical
More informationConditional Early Approval System for Innovative Medical Device Products (Fast-Break Scheme)
PSEHB Notification No. 0731-1 July 31, 2017 To: Prefectural Governors Director-General of the Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare (Official seal
More informationBasic Principles for Conducting Phase I Trials in the Japanese Population Prior to Global Clinical Trials
Administrative Notice October 27, 2014 To: Prefectural Health Department (Bureau) Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Basic
More informationRegulatory Perspectives of Japan
International Alliance for Biological Standardization (IABS) Challenge Toward Sound Scientific Regulation of Cell Therapy Products at Kyoto International Conference Center, Kyoto, Japan Regulatory Perspectives
More informationRegulatory Framework in Japan - Past and Future - Building a Regulatory Framework Essential Elements of Compliance / Surveillance
Regulatory Framework in Japan - Past and Future - Building a Regulatory Framework Essential Elements of Compliance / Surveillance Nobuo UEMURA Director Office of Medical Devices III Pharmaceuticals and
More informationDirector of Evaluation and Licensing Division Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare
Provisional translation (as of March 27, 2008) 1 PFSB / ELD Notification No. 0210004 February 10, 2005 *Revised in accordance with PFSB / ELD Notification No. 0619004 June 19, 2007 Director of Evaluation
More informationPharmaceutical Regulations in Japan
Pharmaceutical Regulations in Japan Tamiji Nakanishi Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare * A Japanese translation is the official
More informationTHE 2005 PHARMA, BIOTECH AND DEVICE COLLOQUIUM THE INTERNATIONAL DRUG SAFETY PARADIGM
THE 2005 PHARMA, BIOTECH AND DEVICE COLLOQUIUM THE INTERNATIONAL DRUG SAFETY PARADIGM June 7, 2005 Shinya Yamauchi Otsuka Pharmaceutical Co., Ltd. 1 Outline Revision of Japan s Pharmaceutical Affairs Law
More informationQuestion and Answer Guide Regarding Notification on Practical Operations of Electronic Study Data Submissions
Administrative Notice April 27, 2015 To: Prefectrual Health Department (Bureau) Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Question
More informationRisk Management Plan Guidance
1 / 17 Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Translated by Office of Safety Ⅰ, Pharmaceuticals and Medical Devices Agency This English version is intended to be
More informationPMDA Update. - New Regulation in Japan and Future Direction of PMDA
PMDA Update - New Regulation in Japan and Future Direction of PMDA Kazuhiro SHIGETO, M.D., M.P.H., Ph.D. Executive Director, Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and
More informationExperiences of a Bioinformatics Company in. Dr Othmar Pfannes 4 November 2016 Basel
Experiences of a Bioinformatics Company in Dr Othmar Pfannes 4 November 2016 Basel Agenda About Genedata Genedata in Japan Q&A 2 Genedata Snapshot Roots Established in 1997 Privately owned Headquartered
More informationNew Direction of Japanese Regulations on MD/IVD. - Japan Update -
New Direction of Japanese Regulations on MD/IVD - Japan Update - Topics Collaboration plan to accelerate review of MDs Revision of Pharmaceutical Affairs Law (PAL); Implementation of PMD Act. 2 Collaboration
More informationof Innovative Pharmaceuticals* and Takao Inoue 4
26G-ISMS44 Regulatory Science for R&D Promotion Kazuhiko Mori 1, Takao Yamori 2, Toru Kawanishi 3, 1 Ministry of Health, Labor and Welfare (MHLW), 2 Pharmaceuticals and Medical Devices Agency (PMDA), 3
More informationNew Regulation in Japan and Future Direction of PMDA. Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA)
New Regulation in Japan and Future Direction of PMDA Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed in the following
More informationEnhancing Review Efficiency (Pharmaceuticals)
Enhancing Review Efficiency (Pharmaceuticals) Naoto Kato Office of Review Management Review Planning Div. ( PMDA ) September 10th, 2015 The 2nd Brazil-Japan Seminar on Regulations on Pharmaceuticals and
More informationSenior Regulatory Affairs Executive AREAS OF EXPERTISE
Senior Regulatory Affairs Executive AREAS OF EXPERTISE More than fifteen years experience in vaccines, pharmaceuticals, biotechnology, and combination device products. Experience in regulatory strategy
More informationGCP/Clinical Investigation in Japan
GCP/Clinical Investigation in Japan 27-28 August, 2018 Shinwa Shibata Office of Non-clinical and Clinical Compliance Pharmaceuticals and Medical Devices Agency 1 Today s Agenda 1. Japanese-GCP (J-GCP)
More informationPre-consultation system at the authority for clinical trials and NDA in Japan
Pharmaceuticals and Medical Devices Agency Pre-consultation system at the authority for clinical trials and NDA in Japan Takeyuki SATO Associate Director, Centre for Product Evaluation Pharmaceuticals
More informationCurrent Status and Perspectives on Pharmaceutical Products in Japan
Current Status and Perspectives on Pharmaceutical Products in Japan Yoshihiro Matsuda, Ph.D. Deputy Division Director Office of Standards and Guidelines Development Pharmaceuticals and Medical Devices
More informationOrphan Designation System in Japan. 10, March 2014 Ministry of Health, Labour and Welfare
Orphan Designation System in Japan 10, March 2014 Ministry of Health, Labour and Welfare Background of the Orphan Designation System Before the system had been implemented, the R&D on medicines for rare
More informationGlobal Clinical Trials in Korea
Global Clinical Trials in Korea In-Sook Park Department of Drug Evaluation Korea Food & Drug Administration Contents Regulatory changes relevant to Clinical Trials in Korea Current Status of Clinical Trials
More informationLatest Trend of Drug Quality in Korea In-Kyu Kim, Ph.D. Division Director Drug Evaluation Department
Latest Trend of Drug Quality in Korea 2008. 4.14 In-Kyu Kim, Ph.D. Division Director Drug Evaluation Department Contents Status of KFDA CMC, GRP and CTD DMF GMP Quality Control on the market International
More informationJapanese Pharmacopoeia s Challenge to the Globalization
Japanese Pharmacopoeia s Challenge to the Globalization Naoyuki Yabana, Ph.D. Division of Pharmacopoeia and Standards for Drugs, Office of Standards and Guidelines Development, Pharmaceuticals and Agency
More information8 th Kitasato- Harvard Symposium
8 th Kitasato- Harvard Symposium CONSISTENT SAFETY RISK MANAGEMENT THROUGH THE PRODUCUT LIFE CYCLE FROM CLINICAL DEVELOPEMNT TO POST APPROVAL - Efforts of Regulatory Authority in Japan - Kaoru Misawa Director,
More informationPost-Approval CMC Changes in Japan: How We Envision the Future
CMC Strategy Forum Summer 2016, July 18-21, 2016, Gaithersburg Marriott Washingtonian Center, Gaithersburg, MD, USA Post-Approval CMC Changes in Japan: How We Envision the Future Yasuhiro Kishioka, Ph.D.
More informationApproval Review of Generic Drugs. Office of Generic/OTC Drugs, PMDA Kazuyuki SAITO, Ph.D.
Approval Review of Generic Drugs Office of Generic/OTC Drugs, PMDA Kazuyuki SAITO, Ph.D. Outline of Presentation Introduction Approval Review of Generic Drugs Equivalency review Conformity audit Conclusion
More informationICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective
ISPE Japan Affiliate 2016 Annual Meeting, April 14-15, 2016, Tower hall Funabori, Tokyo, Japan ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective Yasuhiro Kishioka, Ph.D. Principal
More informationHandling of Marketing Application for Combination Products
October 24, 2014 To: Commissioner of Prefectural Health Department (Bureau) N o t i f i c a t i o n PFSB/ELD Notification No. 1024-2 PFSB/ELD/OMDE Notification No. 1024-1 PFSB/SD Notification No. 1024-9
More informationCMC Strategy Forum Japan November Piyanan Boonprasirt Bureau of Drug Control Thailand Food and Drug Administration
CMC Strategy Forum Japan 2015 9-10 November 2015 Piyanan Boonprasirt Bureau of Drug Control Thailand Food and Drug Administration 1 1. Background 2. Organization Chart 3. Biological Products 4. Regulation
More informationPOSTER PRESENTATIONS & POSTER DISCUSSIONS
POSTER PRESENTATIONS & POSTER DISCUSSIONS Poster Presentation with Short Oral Presentation Short oral presentations are held on November 14 and 15 between 12:10-13:50. Speakers are asked to give the presentation
More informationGuide to Drug Approval System in Korea
Publication registration number 11-1471057-000238-01 Guide to Drug Approval System in Korea April 2017 Abbreviation MFDS : Ministry of Food and Drug Safety NIFDS : National Institute of Food and Drug
More informationPMDA Perspective: Recent Trends in the Regulation of Biopharmaceuticals
PMDA Perspective: Recent Trends in the Regulation of Biopharmaceuticals Takao Yamori, Ph.D. Director of Center for Product Evaluation and Deputy Director General of the Office of Review Innovation PMDA,
More informationPMDA Town Hall. Tatsuya KONDO, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA)
PMDA Town Hall - New Regulation in Japan and Future Direction of PMDA Tatsuya KONDO, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed
More informationCANADA (HEALTH CANADA)
1 GMP GAZETTE TM May 2016 HPFBI CANADA (HEALTH CANADA) No updates NNHPD NHPs Final Monograph for Antiseptic Skin Cleanser Who`s Affected? Companies seeking NPN or DIN for topical antiseptic hand cleansers
More informationPMDA Update: Its current situation and future direction
PMDA Update: Its current situation and future direction Tatsuya Kondo, M.D. Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency Contents 1. Organization 2. Recent Approaches for Innovative
More informationSection I: Pharmaceuticals and Medical Devices
SUPPLEMENT on HEALTHCARE INNOVATION Visionary Goals and Recommendations 51th Japan-U.S. Business Conference Japan-U.S. Business Council / U.S.-Japan Business Council November 14, 2014 The R&D-based pharmaceutical
More informationPMDA Perspectives Yoshihiro Matsuda, Ph.D.
PMDA Perspectives Yoshihiro Matsuda, Ph.D. Office of Standards and Guidelines Development Pharmaceuticals and Medical Devices Agency (PMDA) 1 Introduction of PMDA NAME: Pharmaceuticals and Medical Devices
More informationRecent Update of Medical Products Regulation in Japan
Recent Update of Medical Products Regulation in Japan Masatoshi Narita Councillor for Pharmaceutical Affairs Minister s Secretariat Ministry of Health, Labour and Welfare (MHLW), Japan 2nd Joint conference
More informationType of Activity. Universal Activity Number L04-P
Below are the pharmacy designated Universal Activity Numbers (UANs) and type of activity that is applicable for each of the following program offerings Session # Title 104 Impact of Biologics, Vaccines,
More informationOsamu Komiyama, Kotonari, Aoki, Akira Kokan, Kiyoshi Kubota JSPE Task force for good pharmacovigilance planning in Japan November 5, 2015
Good pharmacovigilance planning in Japan: Proposals from the task force for good pharmacovigilance planning in Japan of Japanese Society for Pharmacoepidemiology (JSPE) Osamu Komiyama, Kotonari, Aoki,
More informationCurrent Status and Perspectives of Placebo-controlled Studies
Provisional Translation (as of June 1, 2016) March 9, 2016 Current Status and Perspectives of Placebo-controlled Studies Subcommittee on Placebo-controlled Studies Kazuhiko Yamamoto, Chairperson Yoshihiro
More informationRegulatory Updates in Taiwan
6th Joint Conference of Taiwan and Japan on Medical Products Regulation Regulatory Updates in Taiwan Shou-Mei Wu, Taiwan Food and Drug Administration Oct. 11, 2018 Outlines 01 02 03 04 05 06 Mission, Vision,
More informationRegulator s Utilisation of Big Data in Pharmacovigilance Activities
Regulator s Utilisation of Big Data in Pharmacovigilance Activities Kazuhiro KAJIYAMA, Ph.D Safety Reviewer Division of Epidemiology Office of Medical Informatics and Epidemiology Pharmaceuticals and Medical
More informationRegulator s Utilisation of Big Data in Pharmacovigilance Activities
Regulator s Utilisation of Big Data in Pharmacovigilance Activities Kazuhiro KAJIYAMA, Ph.D Division of Epidemiology Office of Medical Informatics and Epidemiology Pharmaceuticals and Medical Devices Agency
More informationSaudi FDA Drug Approval Process. Dr. Mohammed A. Alquwaizani Consultant- Chief of the scientific office Saudi Food and Drug Authority
Saudi FDA Drug Approval Process Dr. Mohammed A. Alquwaizani Consultant- Chief of the scientific office Saudi Food and Drug Authority Objective Describe the drug regulation practice in Saudi Arabia and
More informationCurrent Situation of Regulations and Premarket Review in Future of Companion Diagnostics in Japan
Current Situation of Regulations and Premarket Review in Future of Companion Diagnostics in Japan Daisei Miyamoto Pharmaceuticals and Medical Devices Agency(PMDA) Review Director, Office of Medical Devices
More informationPost approval change of Japanese registration dossiers and impact on market supply
Post approval change of Japanese registration dossiers and impact on market supply Table of content Table of content Business model evolution of API sales Challenge on Regulatory compliance Risks of Regulatory
More informationCTA/NDA Regulatory Landscape in China. Jack Xie, PhD, DABT SOT 2016
CTA/NDA Regulatory Landscape in China Jack Xie, PhD, DABT SOT 2016 Disclaimer The content of the following presentation represents solely author s view and may not reflect any position of Roche or China
More information1. GMP/Quality issues Report back from the discussion in last year s symposium
2 nd Japan - India Medical Products Regulation Symposium 1. GMP/Quality issues Report back from the discussion in last year s symposium Mr. Fumihito Takanashi, Office of International Regulatory Affairs
More informationRegulatory frameworks of regenerative medicines and products review in Japan
Regulatory frameworks of regenerative medicines and products review in Japan August 27th, 2018 Kenji KUROIWA Deputy Director, Medical Devices Evaluation Division Ministry of Health, Labour and Welfare,
More informationImplementation of 2005 Pharmaceutical Affairs Law and ICH Q8-Q10 in Japan
JCCT workshop on Q8/Q9/Q10 Beijing Implementation of 2005 Pharmaceutical Affairs Law and ICH Q8-Q10 in Japan Yukio HIYAMA Chief, 3 rd Section, Division of Drugs National Institute of Health Sciences, Ministry
More informationRegulations of Biologics in Taiwan
Regulations of Biologics in Taiwan Churn-Shiouh Gau, Ph.D. Executive Director, Taiwan 2013/2/13 1 Outlines Regulation of Drugs in Taiwan - Organizations Regulations for Marketing Approval for Drugs including
More informationOn the Q&A to the Guideline for Common Technical Documents
To: Public Health Bureau Prefectural Government Letter from PFSB/ELD 22 nd October 2001 From: Evaluation & Licensing Division, Pharmaceutical & Food Safety Bureau, The Ministry of Health, Labour and Welfare
More informationRegulatory requirements for cell based medicinal products
Regulatory requirements for cell based medicinal products 資料 3-2 Committee 25 August 2010 Dr. Bettina Klug, MSc Paul-Ehrlich-Institut, Langen klube@pei.de Paul-Ehrlich-Institut Federal Institute for Vaccines
More informationQMS regulation in Japan. Office of Manufacturing/Quality and Compliance As of 1st April, 2015
QMS regulation in Japan Office of Manufacturing/Quality and Compliance As of 1st April, 2015 Manufacturing/Quality and Compliance Manufacturing/Quality and Compliance QA of GMP/QMS GMP QMS KANSAI Branch
More informationReport of the Advisory Panel for Promotion of Medical Ventures (Summary)
Report of the Advisory Panel for Promotion of Medical Ventures (Summary) Report of the Advisory Panel for Promotion of Medical Ventures (Summary) Innovation is a key trigger for Japan s economic growth
More informationRegulation of Cell and Gene Therapy Products in Canada
Regulation of Cell and Gene Therapy Products in Canada Canadian Blood and Bone Marrow Transplant Group June 8, 2018 Nadine Kolas, PhD Senior Policy Analyst Blood, Cells, Tissues and Organs Biologics and
More informationCurrent Topics of Pharmaceutical Regulatory Affairs in Japan
Pharmaceuticals and Medical Devices Agency Current Topics of Pharmaceutical Regulatory Affairs in Japan Takeyuki SATO Associate Director (International and Product Evaluation Affairs), Centre for Product
More informationCurrent Challenges of Regulation in Japan - Amendment of Pharmaceutical Affairs Act
Current Challenges of Regulation in Japan - Amendment of Pharmaceutical Affairs Act Hiroshi Yamamoto, MS Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA), Japan 26th Annual EuroMeeting
More informationNam Soo, Kim. Biopharmaceutical Policy Division
Drug Approval and Review System in Korea Jun. 30, 2017 Nam Soo, Kim Biopharmaceutical Policy Division [ Table of Contents] Introduction of MFDS Overview of Drug Approval System Recent Changes for Safety
More informationHow are medicines evaluated at the EMA
How are medicines evaluated at the EMA Presented by: Nathalie Bere Patient interaction / Stakeholders and communication Division An agency of the European Union The European System Centralised Procedure
More informationGuidance on Drug Master File System in Japan
Guidance on Drug Master File System in Japan Master File Management Group Division of Pharmacopoeia and Standards for Drugs Office of Review Management 1 Notes In Japan, the Drug Master File (DMF) is called
More informationEMEA/AD/258: Head of Sector Pharmacovigilance and Risk Management of Medicinal Products for Human Use (AD9).
EMEA/AD/258: Head of Sector Pharmacovigilance and Risk Management of Medicinal Products for Human Use (AD9). Responsible, under the Head of Unit for the Post-Authorisation Evaluation of Medicinal Products
More informationCurrent GMP Inspection of PMDA. Shingou SAKURAI, Ph.D Office of Compliance and Standards Pharmaceuticals and Medical Devices Agency(PMDA), JAPAN
Current GMP Inspection of PMDA Shingou SAKURAI, Ph.D Office of Compliance and Standards Pharmaceuticals and Medical Devices Agency(PMDA), JAPAN GMP Inspection related Organizations in Japan Organizations
More informationHosting Inspections from foreign countries: PMDA (Japan) ANVISA (Brazil)
Hosting Inspections from foreign countries: PMDA (Japan) ANVISA (Brazil) Kathrin Abelein Vice President Quality, R-Pharm, JSC First Russian GMP Conference 20. 22. September 2016 Agenda General information
More informationUNIVERSITY OF MUMBAI
Academic Council 25/05/2011 Item No. 4.71 UNIVERSITY OF MUMBAI Syllabus for Clinical Studies Program: Diploma Course: Post Graduate Diploma in Clinical Studies, Data Management & Medical Writing (Introduced
More informationRegulatory Reform for Regenerative Medicine in Japan
Pharmaceuticals and Medical Devices Agency Regulatory Reform for Regenerative Medicine in Japan Daisaku Sato, PhD. Director, Office of Cellular and Tissue-based Products Pharmaceuticals and Medical Devices
More informationThe 6 th Kitasato-Harvard Symposium Session3:New Challenges Disease Areas. Investigator Initiated Trial (IIT) Future for IIT from the past experience
The 6 th Kitasato-Harvard Symposium Session3:New Challenges Disease Areas Investigator Initiated Trial (IIT) Future for IIT from the past experience JMACCT Project Clinical Trial Research Project of JMACCT
More informationCMC Workshop CMC Challenges in Japan. April Bethesda, MD. Yoshihiro Matsuda, Ph.D., PMDA Session 10
CMC Workshop 2015 April 13-15 Bethesda, MD CMC Challenges in Japan Yoshihiro Matsuda, Ph.D., PMDA Session 10 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of
More informationSection I: Creating a more Transparent and Predictable Environment for Innovation to Continue Improving People s Health Worldwide
SUPPLEMENT on HEALTHCARE INNOVATION 54th U.S.-Japan Business Conference The U.S.-Japan Business Council / Japan-U.S. Business Council November 3, 2017 Executive Summary Section I: Creating a more Transparent
More informationPharmacist Rana Musa Al-ali (Malkawi) MSc (Pharmaceutical Quality Assurance) Registration Department/JFDA
Pharmacist Rana Musa Al-ali (Malkawi) MSc (Pharmaceutical Quality Assurance) Registration Department/JFDA 1 2 ND MENA Regulatory Conference On Bioequivalence, Biowaivers, Bioanalysis, Dissolution & Biosimilars
More informationOverview of global registration of vaccines
Overview of global registration of vaccines by Dr. Nora Dellepiane Workshop: Global Registration and Vaccine Shortage Taipei, Taiwan 6 to 10 March 2017 Outline of the presentation The objective of medicines
More informationRegulatory requirements and registration process of Generic Drugs in China
13 Regulatory requirements and registration process of Generic Drugs in China Jitendra Kumar Badjatya Deputy Manager-DRA, Montajat Pharmaceutical Company Limited, Dammam, KSA jeetbadjatya@gmail.com ABSTRACT
More informationTo: Prefectural Governors From: Director-General, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare
Provisional Translation (as of March 2010) PFSB (Yakushoku) Notification No. 0216002 February 16, 2005 To: Prefectural Governors From: Director-General, Pharmaceutical and Food Safety Bureau, Ministry
More informationSafety reporting requirements in the post marketing phase. Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington
Safety reporting requirements in the post marketing phase Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington DISCLAIMER These materials have been prepared solely for educational
More informationGMP. Safeguard The Patient s Health.
GMP Safeguard The Patient s Health. Scope. Products and testing according to pharma industry standard. Good Manufacturing Practice or GMP are practices and systems that are required to be adapted in pharmaceutical
More informationDocumentation requirements for an initial consultation
Language : French or English Documentation requirements for an initial consultation Because of the wide range of medical devices which incorporate, as an integral part, an ancillary medicinal substance,
More informationFOOD REGULATION ON AGROCHEMICALS FOR ENSURING QUALITY AND SAFETY OF FOOD SUPPLY IN JAPAN
FOOD REGULATION ON AGROCHEMICALS FOR ENSURING QUALITY AND SAFETY OF FOOD SUPPLY IN JAPAN Shoji Miyagawa Inspection and Safety Division, Department of Food Safety Pharmaceutical and Food Safety Bureau Ministry
More informationDi Renzo Regulatory Affairs ROME - MILAN - LONDON
Di Renzo Regulatory Affairs ROME - MILAN - LONDON Di Renzo Regulatory Affairs In 1985, Di Renzo Regulatory Affairs began its regulatory consulting for medicines for human and veterinary use, food and dietary
More informationOVERVIEW OF DIRECTIVE 2001/20. Paul Derbyshire. Background & History. Aims of Directive 2001/20
OVERVIEW OF DIRECTIVE 2001/20 Paul Derbyshire Background & History CONDUCT OF TRIALS III/3976/88 (July 1991) ICH/135/95 (January 1997) 2001/20 75/318 Q,S,E Testing Part 4B: GCP 91/507 MEDICINAL PRODUCTS
More informationPMDA s perspective on regulatory science in pharmaceutical regulation
PMDA s perspective on regulatory science in pharmaceutical regulation Dr Yoshiaki Uyama Director, Office of Medical Informatics and Epidemiology Pharmaceuticals and Medical Devices Agency (PMDA) Visiting
More informationCell and Gene Therapy Medicinal Product Management Act (Draft) General Information
Cell and Gene Therapy Medicinal Product Management Act (Draft) General Information July 2017 At present there are still many diseases that cannot be cured by current medical technology and existing chemical
More informationIntroduction of Ministry of Health, Labour and Welfare (MHLW) / Pharmaceuticals and Medical Devices Agency (PMDA) and recent updates in Japan
Introduction of Ministry of Health, Labour and Welfare (MHLW) / Pharmaceuticals and Medical Devices Agency (PMDA) and recent updates in Japan 2 nd meeting of Commission Expert Group on Safe and Timely
More informationDRUG APPROVAL PROCESSES IN PHARMACEUTICAL MARKET
INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Research Article DRUG APPROVAL PROCESSES IN PHARMACEUTICAL MARKET J. Yoshasri *, M. Sai Kusuma and A. Elphine
More informationRegulatory considerations for Global Haplobank
Regulatory considerations for Global Haplobank Jacqueline Barry Catapult is an Innovate UK programme. GTP Good Practice GMP GLP, GCP, GVP Cell & Tissue Procurement MCB production Manufacture to clinical
More information